Please login to the form below

Not currently logged in

Dr Michael Watson appointed as president of Valera

Former Sanofi Pasteur policy head joins Moderna Therapeutics firm

Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president.

Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.

Stéphane Bancel, chief executive officer of Moderna, said: “We are thrilled to have Mike assume the helm of Valera, particularly at this critical inflection point for the company, as we continue to progress our clinical stage infectious disease pipeline.”

He joins the infectious diseases specialty firm from Sanofi Pasteur, where he most recently served as its global head of vaccination policy and advocacy and has also held the position of head of clinical and epidemiology in France.

Prior to this, Dr Watson has been head of research and development at Acambis and Aventis Pasteur MSD's medical director for the UK.

He is currently a member of the Board of Vaccines Europe and The Foundation for Innovative New Vaccines.

Dr Watson said: “The potential for mRNA therapeutics to meaningfully address some of the world's most pressing infectious disease concerns is truly exciting.

“Moderna's technology, coupled with its goal to deliver transformative medicines to millions of patients, makes this an extraordinary opportunity.

“I am eager and proud to join Valera and work with this outstanding team and Moderna's esteemed infectious disease-focused partners.”

13th April 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge